NTRA INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses...
SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. NTRA investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now.
Class Period: Feb. 26, 2020 Apr. 19, 2022
Lead Plaintiff Deadline: June 27, 2024
Visit: www.hbsslaw.com/investor-fraud/NTRA
Contact An Attorney Now: [email protected]
844-916-0895
Natera, Inc. NTRA Securities Fraud Class Action:
Defendants have repeatedly claimed that its screening test for kidney transplant failure (Prospera) was superior to competitors' tests and that its non-invasive prenatal test (Panorama) was reliable.
According to the complaint, Defendants misrepresented or failed to disclose that: (1) Panorama was not reliable and resulted in high rates of false positives; (2) Prospera did not have superior precision compared to competing tests; (3) as a result of Defendants' false and misleading claims about Natera's technology, the company was exposed to substantial legal and regulatory risks; and, (4) Natera relied upon deceptive sales and billing practices to drive its revenue growth.
On Jan. 1, 2022, reported that positive results for genetic disorders such as DiGeorge and Prader-Willi syndromes when using Natera's test are incorrect more than 80% of the time.
On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
Continue read on benzinga.com